Design Therapeutics, Inc.DSGNNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-29.8%
5Y CAGR-34.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-29.8%/yr
Annual compound
5Y CAGR
-34.0%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 33.32% |
| 2024 | -22.28% |
| 2023 | 17.38% |
| 2022 | 96.19% |
| 2021 | 308.88% |
| 2020 | 266.38% |
| 2019 | 0.00% |